Mereo Biopharma Group Plc MREO 深 滬
已收盤 07-18 16:00:00 美东时间
1.77
-0.010
-0.56%
華盛通- 最 高1.87
- 今 開1.79
- 成交量 237.05万股
- 最 低 1.75
- 昨 收 1.78
- 總市值 2.81亿
- 52周最高 5.02
- 市盈率 靜 --
- 換手率 1.49%
- 52周最低 1.57
- 委 比 59.48%
- 總股本 1.59亿
- 歷史最高 17.62
- 量 比 0.48
- 振 幅 6.74%
- 歷史最低 0.301
- 每 手 1
- 風險率 0.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.
07-11 02:36
Mereo BioPharma’s Phase 3 Study Progresses Smoothly
An announcement from Mereo Biopharma Group Plc ( ($MREO) ) is now available. On...
07-10 19:18
Biggest stock movers Thursday: KLG, DAL, and more
Stock futures searched for direction in Thursday’s premarket session as traders digested President Trump’s latest tariff salvo, including a 50% duty on copper imports set to begin August 1 and a threa...
07-10 18:52
Ultragenyx And Mereo BioPharma To Complete Phase 3 UX143 Trials In Osteogenesis Imperfecta By Year-End; Data Monitoring Committee Supports Continued Study With Safety Profile
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO), today announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in
07-10 04:08
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
Ultragenyx and Mereo BioPharma announce progress in their Phase 3 Orbit and Cosmic studies for UX143 (setrusumab) in patients with osteogenesis imperfecta (OI), with final data expected around year-end. The Data Monitoring Committee confirmed the drug's safety, supporting continued research. Setrusumab aims to increase bone mass and reduce fractures by targeting sclerostin. Patients will complete at least 18 months of therapy before final analysi...
07-09 20:05
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Shares of Credo Technology Group Holding Ltd (NASDAQ:CRDO) rose sharply in toda...
06-03 18:30
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $7 price target.
05-13 22:01
Mereo BioPharma Group Q1 EPS $(0.02) Beats $(0.54) Estimate
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.54) by 96.3 percent. This is a 100 percent decrease over losses of $(0.01) per share
05-13 19:33
美股大行评级 | 潜在涨幅345.1%！Corvus Pharma获Oppenheimer升目标价至15美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1112300378952404993.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Corvus Pharma(CRVS)"跑赢大市"评级，目标价从14美元升至15美元</p> <p>• 富国银行：上调Regulus Therapeutics(RGLS)评级至"超配"，目标价从
03-28 09:06
